Dr. Alexandre Hirayama presents on CAR-T cell therapy at ASH 2021 Pt. 2

SCCA's Dr. Alexandre Hirayama presents his poster, Pharmacodynamic Analysis of CAR-T Cell Persistence in Patients with Hematologic Malignancies Treated with NKTR-255, an IL-15 Receptor Agonist That Enhances CD8+ T-Cells: Preliminary Results from a Phase 1 Study at the 63rd ASH Annual Meeting and Exposition. Learn more about SCCA's appearance at ASH 2021 at www.seattlecca.org/conference...

[@silvialogan9226]

Would Car T-Cell immunotherapy be used in the end to treat solid cancers too?